Brii Biosciences Provides Update on Strategic Clinical Development Progress
- Written by PR Newswire
![]() |
Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination studies expected in the first half of 2023
Initiation of Phase 2 postpartum depression (PPD) study planned for early 2023 to advance potential first-of-its-kind treatment
U.S. FDA lifted clinical hold on BRII-732 allowing the Company to reinitiate a...
Read more: Brii Biosciences Provides Update on Strategic Clinical Development Progress















